The best of times, the worst of times for psychiatric disease

Maria Karayiorgou, Jonathan Flint, Joseph A. Gogos, Robert C. Malenka, Cornelia I. Bargmann, Edward S. Boyden, Edward T. Bullmore, Anthony W. Chan, Michael Davis, Karl Deisseroth, Ricardo E. Dolmetch, Kevin Eggan, Scott C. Fears, Nelson B. Freimer, Daniel H. Geschwind, Joshua Gordon, Debbie A. Nickerson, Pierre Vanderhaeghen, Richard Axel, Charles S. ZukerGerald D. Fischbach

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

As long-awaited advances in psychiatric genetics begin to materialize in force, promising to steer us safely to the best of times in psychiatric disease research, many pharmaceutical companies pull away from the challenge of drug development, threatening to bring us to the worst of times for the field. There is a real danger of missed opportunities and a sense of urgency for defining a clear path forward.

Original languageEnglish
Pages (from-to)811-812
Number of pages2
JournalNature Neuroscience
Volume15
Issue number6
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'The best of times, the worst of times for psychiatric disease'. Together they form a unique fingerprint.

Cite this